Evidence map›Paper›PMID 29226181›Full record

ArticleBio-protocol2017

A Bioreactor Method to Generate High-titer, Genetically Stable, Clinical-isolate Human Cytomegalovirus.

Victoria R Saykally, Luke I Rast, Jeff Sasaki, Seung-Yong Jung, Cynthia Bolovan-Fritts, Leor S Weinberger

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. A molecular mechanism for probabilistic bet hedging and its role in viral latency.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Victoria R SaykallyGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
Luke I RastGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
Jeff SasakiGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
Seung-Yong JungGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
Cynthia Bolovan-FrittsGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
Leor S WeinbergerGladstone Institute for Virology and Immunology, University of California, San Francisco, California, USA.
University of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Evolvable 'Resistance-Proof' TherapiesDP1DE024408 · NIDCR · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2013 to 2017
$4.8M
Developing Transmissible Antivirals by Exploiting Gene-Expression CircuitryDP2OD006677 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINBERGER, LEOR S · 2009 to 2009
$2.3M
Stochastic Gene Expression in Retroviral LatencyR01AI109593 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2014 to 2018
$2.2M
NIAID NIH HHS P30 AI027763NIDCR NIH HHS DP1 DE024408NIH HHS DP2 OD006677
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in transplant patients and a leading cause of congenital birth defects (Saint Louis, 2016). Vaccination and therapeutic studies often require scalable cell culture production of wild type virus, represented by clinical isolates. Obtaining sufficient stocks of wild-type clinical HCMV is often labor intensive and inefficient due to low yield and genetic loss, presenting a barrier to studies of clinical isolates. Here we report a bioreactor method based on continuous infection, where retinal pigment epithelial (ARPE-19) cells adhered to microcarrier beads are infected in a bioreactor and used to produce high-titers of clinical isolate HCMV that maintain genetic integrity of key viral tropism factors and the viral genome. In this bioreactor, an end-stage infection can be maintained by regular addition of uninfected ARPE-19 cells, providing convenient preparation of 10

Indexed as

BioreactorClinical isolateContinuous infection cultureHuman cytomegalovirusMicrobeads (Microcarrier beads)Viral tropism

Identifiers

PMID29226181
PMCPMC5718198
OpenAlexW2767072761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.